When zolbetuximab’s price (100 mg) drops below 18.33% of the predetermined price, i.e., below $43.72, ZOL-FO will be a cost-effective first-line treatment option for CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma. Here, ERBB2 is linked to adenocarcinoma.